Abstract

Complications associated with the use of bisphosphonate (BP) have risen over the years due to an increase in the prescription of BP. BP-related osteonecrosis of jaw (BRONJ), one of the complications linked to the consumption of BP, greatly affects patients with minor dental trauma, incurring a long healing period. While BRONJ afflicts only a minority of patients prescribed with BP, BRONJ is a multigenic disease affected both by environmental and genetic factors having a distinctive phenotype. This study aims to discover genetic biomarkers associated with BRONJ via whole exome sequencing (WES) followed by statistical analysis. Sixteen individuals who had been prescribed with bisphosphonate medication and diagnosed as BRONJ were chosen and each individualā€™s saliva sample was collected for WES. 126 randomized subsamples from the GSK project representing 109 male and 17 female Koreans were used as a control data set. Fisherā€™s exact test was carried out to assess the significance of genetic variants in BRONJ patients. Gene set enrichment analysis (GSEA) (DAVID Bioinformatics Resource 6.7) was used to perform a cluster analysis of variants found from Fisherā€˜s exact test. The results from this study suggest that BRONJ-inducing factors are genetically associated and BRONJ occurs due to the malfunctioning of post-translational modification in osteoclast leading to the impairment of cell morphology and adhesion.

Highlights

  • Bisphosphonates (BP) are a commonly prescribed medication to treat bone metastases, multiple myeloma, osteoporosis, and other bony diseases [1,2,3]

  • The selection yielded 219,722 variants, which were processed to find impact variants. 69,187 variants were found to match the criteria, 13,325 variants showing significance based on Genomic Evolutionary Rate Profiling (GERP) and polyPhen scores

  • Variants chosen were selected for subsequent gene set enrichment analysis

Read more

Summary

Introduction

Bisphosphonates (BP) are a commonly prescribed medication to treat bone metastases, multiple myeloma, osteoporosis, and other bony diseases [1,2,3]. It is prescribed at 73 percent of physician visits for osteoporosis in the United States [4]. No significant side effects have been reported but patients prescribed with BP over a long period tend to experience complications.

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call